All News
An exciting year and time for GCA and PMR treatment!
- Tocilizumab (IL-6i)
- Secukinumab (IL-17i)
- Sarilumab (IL-6i)
- Mavrilimumab (GM-CSF receptor mAb)
- Tofacitinib (JAKinib)
@RheumNow #RNL2023 https://t.co/d0T2RAssFY
Mar 19, 2023
@RheumNow's review of new drug approvals during 2022 at #RNL2023 https://t.co/IgndlG6lOI
Mar 19, 2023
Extension PEXIVAS study in ANCA vasculitis pts with severe DAH
- no significant effect of PLEX on mortality but do note numerical difference, favoring PLEX in severe DAH
- note difference in curve
@RheumNow #RNL2023 https://t.co/6ktb3Uakw9
Mar 19, 2023
Biosimilars are coming!
Multiple adalimumab biosimilars this year
- will we see a dramatic price difference?
@RheumNow #RNL2023 https://t.co/8vdtXtEGOO
Mar 19, 2023
Biosimilars back on the radar for 2023. Expect to see 17 in rheum. #RNL2023 @RheumNow https://t.co/SNYNM8nmD2
Mar 19, 2023
Biosimilar to biosimilar switching of Infliximab , @RheumNow Kavanaugh #RNL2023
Communications is a key always.
Discuss with your patient always, and show them the data. https://t.co/d7Nq6LoJYQ
Mar 19, 2023
Will be begin using sputum instead of blood serologies to detect RA?
- sputum seropositive CCP may be associated with development of clinical RA
- 4 fold higher risk if (induced) sputum CCP+
@RheumNow #RNL2023 https://t.co/Z85GDwIyl8
Mar 19, 2023
#RNL2023 Year in Review
Sputum antibody predicts future development of RA
Hazard ratio 4.2 if any sputum antibody positive (CCP IgG/IgA, RF IgM and IgA)
Strongest association with CCP IgA
Supports pre-RA as mucosal disease
@RheumNow https://t.co/Js4JPZiLDB
Mar 19, 2023
How does HCQ work
@Lupusreference in #RNL2023
HCQ works by inhibition of Toll-like receptor (TLR) with affects on IFN
HCQ works as base to increase lysosomal pH and affect cellular function
@RheumNow https://t.co/RTEUF0cS0u
Mar 19, 2023
@Lupusreference in #RNL2023
HCQ and arrhythmia via QTc prolongation
At normal doses, same as general population
If on other QTc prolonging medications, a baseline EKG may be beneficial
@RheumNow https://t.co/cAN2vBNa1t
Mar 19, 2023
Any dose more than 1500 is associated with retinopathy ? So what to do. @Lupusreference #RNL2023 @RheumNow https://t.co/2zdjpcuvKa
Mar 19, 2023
Smoking and SLE
Smoking increases SLE activity
Smoking decreases HCQ efficacy
Skin response on HCQ down 50% in smokers 🚬
@Lupusreference #RNL2023 @RheumNow
Mar 19, 2023
TULIP trials in lupus, disease outcomes and others, by Richard Furie #RNL2023 @RheumNow https://t.co/uUQOxUIzJN
Mar 19, 2023
Dr. Furie: #RNL2023
Anifrolumab - anti type 1 IFN receptor- blocks all 5 IFN, 90% IFN gene signature decrease
Improved from prior older failed medication sifalimumab which only blocked IFNalpha- only 25% interferon gene signature
@RheumNow https://t.co/30oFRwwuTG
Mar 19, 2023
✅ Check my TAKE-HOME MESSAGES about #hydroxychloroquine & #Lupus for RheumNow Live 2023 #RNL2023
@RheumNow ⬇️ https://t.co/E2xdv3ODG6
Mar 19, 2023
SRI Responders more likely able to reduce prednisone and far
Serological improvement
SF-36
Fatigue
by Richard Furie #RNL2023 @RheumNow https://t.co/ilsyOXw7nA
Mar 19, 2023
Compliance is always an issue, by Richard Furie #RNL2023 @RheumNow .
Plaquenil level were below target. Adherence is always something we need to work on. https://t.co/hMgL9kY0rZ
Mar 19, 2023
Dr. Ken Kalunian on Lupus nephritis
Don't forget about ACEi/ARB therapy for SLE pts with renal involvement
- can control BP
- reduce Urine proteinuria
- decrease risk of active renal disease
#RNL2023 @RheumNow https://t.co/hLBqjELqW2
Mar 19, 2023
UPCR< 500 mg is the best predictor of a renal outcome in lupus nephritis. Multiple creatinine testing, Ken Kalunian #RNL2023 @RheumNow https://t.co/96PlXgqOfK
Mar 19, 2023
Belimumab in Active lupus nephritis , Ken Kalunian #RNL2023 @RheumNow https://t.co/VZkmK8Iny7
Mar 19, 2023